Novavax Files 8-K Report

Ticker: NVAX · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1000694

Novavax Inc 8-K Filing Summary
FieldDetail
CompanyNovavax Inc (NVAX)
Form Type8-K
Filed DateNov 20, 2024
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-K

Related Tickers: NVAX

TL;DR

Novavax filed a routine 8-K, no major news.

AI Summary

On November 19, 2024, Novavax, Inc. filed an 8-K report to disclose information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates Novavax is adhering to its reporting obligations with the SEC, providing transparency to investors.

Risk Assessment

Risk Level: low — This is a standard regulatory filing with no new material information that would immediately impact the company's risk profile.

Key Players & Entities

  • NOVAVAX, INC. (company) — Registrant
  • November 19, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 700 Quince Orchard Road Gaithersburg, Maryland 20878 (address) — Principal Executive Offices

FAQ

What is the purpose of this 8-K filing by Novavax, Inc.?

The purpose of this 8-K filing is to report information under Regulation FD and to file financial statements and exhibits.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is November 19, 2024.

In which state is Novavax, Inc. incorporated?

Novavax, Inc. is incorporated in Delaware.

What is Novavax, Inc.'s principal executive office address?

Novavax, Inc.'s principal executive office is located at 700 Quince Orchard Road, Gaithersburg, Maryland 20878.

What is Novavax, Inc.'s telephone number?

Novavax, Inc.'s telephone number is (240) 268-2000.

Filing Stats: 1,543 words · 6 min read · ~5 pages · Grade level 15.6 · Accepted 2024-11-19 20:01:22

Key Financial Figures

  • $0.01 — registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Se

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On November 20, 2024, Novavax, Inc. (the "Company") will provide an update for investors at the 2024 Jefferies London Healthcare Conference, sharing information relating to certain strategic and business updates (the "Investor Presentation"), which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. A copy of the Investor Presentation will also be accessible on the Company's website at www.novavax.com under "Latest Investor Presentation." Cautionary Note Regarding Forward-Looking Statements . This Current Report on Form 8-K and the Investor Presentation attached as Exhibit 99.1 include forward-looking statements including statements related to our corporate strategy and operating plans, objectives and prospects; our value drivers and near-term priorities; our partnerships, including expectations with respect to potential royalties, milestones, and cost reimbursement, and plans for additional potential partnering activities; our expectations regarding manufacturing capacity, timing, production and delivery for our COVID-19 vaccine; the development of our clinical and preclinical product candidates and innovation expansion opportunities; the conduct, timing and potential results from clinical trials and other preclinical studies; scope, timing and outcome of future and pending regulatory filings and actions; potential market sizes and demand for our COVID-19 vaccine and product candidates; full year 2024 financial guidance; expected combined annual R&D and SG&A expenses for 2025 and 2026; the amount and impact of our cost reduction plans; our future financial or business performance; plans with respect to our existing advanced purchase agreements; and the potential sale of our Czech Republic manufacturing facility. Generally, forward-looking statements can be identified through the use of words or phrases such as "believe," "may," "could," "will," "would," "possible,

Forward-looking statements are neither historical facts nor assurances

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs and expectations about the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements. Such risks and uncertainties include, without limitation, our ability to successfully and timely manufacture, market, distribute, or deliver our updated 2024-2025 formula COVID-19 vaccine and the impact of our not having received a BLA from the FDA for the 2024-2025 vaccination season; challenges related to our partnership with Sanofi and in pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials or studies for our product candidates, including increased costs associated with the Phase 3 trial for our CIC and stand-alone influenza vaccine candidates; challenges or delays in obtaining regulatory authorization for our product candidates, including for future COVID-19 variant strain changes, our CIC vaccine candidate, our stand-alone influenza vaccine candidate or other product candidates; manufacturing, distribution or export delays or challenges; our substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling our COVID-19 vaccine and the impact of any delays or disruptions in their

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Investor Presentation of Novavax, Inc. 104 Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Novavax, Inc. Date: November 19, 2024 By: /s/ Mark Casey Name: Mark Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.